Eupraxia Pharmaceuticals Inc EPRX

$7.59 +0.64 (9.21%)

Valuation

Market cap
451,882,000
Revenue TTM
$0
Net income TTM
$-38,580,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
938,600
Avg volume
691,660
Day's range
$6.87 – $7.76
Shares out
65,019,000
Stochastic %K
87%
Beta
0.83
Analysts
Strong Sell
Price target
$16.65

Price

Company profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI...

Show more

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
250 590 3968
Website
https://www.eupraxiapharma.com
Address
2067 Cadboro Bay Road, Suite 201, Victoria, Canada

Latest news

Stocktwits

Quantumup Oct 20, 8:18 PM
Oppenheimer reiterated $EPRX Outperform-$17 AMGN - $AZN $REGN - SNY PHAT TRAX BMY ABBV Here's what Oppenheimer had to say in its note: https://x.com/Quantumup1/status/2112639499721117886?s=20
0 replies
jheerdink Oct 20, 7:29 PM
$EPRX "With 120 patients enrolled in its Phase 2b study, Eupraxia’s drug-delivery platform moves toward a consequential clinical test." https://vistapglobal.com/eupraxia-pharmaceuticals-hits-resolve-enrollment-target-as-december-eoe-data-come-into-focus-eprx-xbi-ibb/
0 replies
money789 Oct 20, 12:16 PM
$EPRX tic toc tic toc!
0 replies
Merlintrader Oct 17, 10:29 PM
Eupraxia Pharmaceuticals $EPRX: The RESOLVE Test Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/eupraxia-pharmaceuticals-stock-hub/
0 replies
jheerdink Oct 16, 4:28 PM
$EPRX https://vistapglobal.com/eupraxia-pharmaceuticals-hits-resolve-enrollment-target-as-december-eoe-data-come-into-focus-eprx-xbi-ibb/
0 replies
jheerdink Oct 15, 2:42 PM
Eupraxia Pharmaceuticals $EPRX Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis https://finance.yahoo.com/healthcare/articles/eupraxia-pharmaceuticals-reaches-enrollment-target-120000356.html
0 replies
focafoca99 Oct 15, 12:38 PM
$EPRX reached its RESOLVE Phase 2b enrollment target of 120 patients, a key milestone for its EP-104GI EoE trial.
0 replies
filecrux Oct 15, 12:34 PM
$EPRX (Eupraxia, clinical-stage biotech testing EP-104GI, injected into the esophageal wall for eosinophilic esophagitis) says in-house reviews of unblinded Phase 2b RESOLVE data found the 120-patient sample size needs no increase; patient 120 was dosed Oct. 12. Market value ~$342.3M at $6.59 (16:00 ET, Oct. 14, 2026); cash $80.6M at Dec. 31, 2025. But a company team ran the reviews and gave no efficacy numbers. Interim on the first 60 Phase 2b patients at 6 months is due December 2026.
0 replies